Damora Therapeutics, Inc. (DMRA) Key Metrics
DMRA valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $1.14B
- Enterprise value
- $1.42B
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- —
- Price / book
- 3.3
- EV / EBITDA
- 0.5
- Dividend yield
- —
- Beta
- 1.44
DMRA key metrics, 2018–2025
Fiscal year ended December 31, 2025 · U.S. dollarsDMRA returns How much profit the business earns on the capital it uses.
DMRA financial health Debt, liquidity and how easily interest is covered.
DMRA efficiency & capital use Working capital cycle and where the cash goes.
DMRA returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
DMRA debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
DMRA key metrics
2018–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||
| Share price at fiscal year-end | $23.01 | $4.65 | $18.00 | $28.75 | $75.75 | $312.75 | — | — |
| Returns & profitability | ||||||||
| Return on equity (ROE) | −164.7% | −91.6% | −81.5% | −68.9% | −36.6% | −32.6% | −92.3% | −51.8% |
| Return on invested capital (ROIC) | — | — | — | −478.5% | −398.6% | −131.9% | −165.8% | — |
| Return on assets (ROA) | −151.1% | −77.5% | −68.8% | −63.1% | −35.2% | −30.5% | −79.6% | −45.2% |
| Return on tangible assets | −80.5% | −125.1% | −100.3% | −84.2% | −42.3% | −20.3% | −64.5% | −45.2% |
| Financial health | ||||||||
| Total debt | $68,000 | $1.4M | $249,000 | $804,000 | $847,000 | $915,000 | $298,000 | — |
| Cash & short-term investments | $257.6M | $14.2M | $33.2M | $60.2M | $100.2M | $163.6M | $11.3M | $31.0M |
| Net debt | −$257.6M | −$12.7M | −$32.9M | −$59.4M | −$99.3M | −$162.7M | −$11.0M | −$31.0M |
| Debt / equity | 0.00 | 0.10 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | — |
| Debt / assets | 0.00 | 0.08 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | — |
| Current ratio | 12.98 | 14.07 | 6.31 | 5.75 | 24.23 | 30.42 | 7.07 | 7.87 |
| Quick ratio | 12.98 | 14.07 | 6.31 | 5.75 | 24.23 | 30.42 | 7.07 | 7.87 |
| Interest coverage | — | — | — | — | — | — | — | -4.3 |
| Working capital | $240.4M | $15.6M | $30.9M | $52.8M | $105.6M | $163.7M | $48.2M | $30.5M |
| Invested capital | −$17.2M | $1.7M | −$571,000 | $2.3M | $17.9M | $2.8M | $37.5M | −$327,000 |
| Tangible asset value | $240.4M | $14.5M | $32.3M | $61.8M | $117.2M | $165.5M | $48.5M | $30.7M |
| Net current asset value | $240.3M | $14.2M | $30.9M | $52.5M | $105.1M | $163.2M | $47.9M | $30.5M |
| Capital allocation | ||||||||
| Capex / depreciation | 0.00 | 0.00 | 0.00 | 0.40 | 0.51 | 0.00 | 0.00 | — |
| Efficiency | ||||||||
| Days payables outstanding | 4,406.8 | 2,096.2 | 1,110.8 | 1,817.9 | 1,813.4 | 5,999.2 | 7,798.2 | — |
| Receivables turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables turnover | 0.08 | 0.17 | 0.33 | 0.20 | 0.20 | 0.06 | 0.05 | — |
| Asset turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average receivables | $890,000 | $1.3M | $1.5M | $1.8M | $2.2M | $21.7M | $21.1M | $989,000 |
| Average payables | $410,500 | $1.0M | $2.5M | $2.4M | $2.2M | $3.1M | $2.4M | $1.4M |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from DMRA's annual financial statements (latest annual report filed December 31, 2025) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
DMRA valuation and financial ratios
Damora Therapeutics earned a return on equity of −164.7% in fiscal 2025. It ended the year with $0.1 million of debt and $257.6 million in cash and short-term investments, a net cash position of $257.6 million.
See the DMRA income statement, the DMRA chart for price history, or the DMRA stock overview for the latest quote and news.
DMRA key metrics FAQ
What is Damora Therapeutics's return on equity?
Damora Therapeutics's return on equity (ROE) was −164.7% in fiscal 2025: net income of -$209.8 million on average shareholders' equity of $127.4 million.
How much debt does Damora Therapeutics have?
Damora Therapeutics had total debt of $0.1 million at the end of fiscal 2025, a debt-to-equity ratio of 0.00 and more cash than debt.
What is Damora Therapeutics's current ratio?
Damora Therapeutics's current ratio was 12.98 at the end of fiscal 2025: current assets were 12.98 times current liabilities.